Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first-in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming months as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: CLBS12, recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).

**INVESTMENT HIGHLIGHTS**

- **CD34+ cell therapy company with an advanced clinical pipeline with 2 programs with “breakthrough” designation and 1 targeting COVID-19 induced lung repair**
- **Proprietary field-leading technology in multi-billion dollar global indications backed by a strong IP portfolio**
- **Multiple potential value creating events in the next 12-18 months based on development milestones across the pipeline (some timing COVID-19 dependent)**
- **Seasoned management team with noteworthy domain expertise along with big pharma and emerging biotech experience**
- **Strong balance sheet; ~$34 million in cash and cash equivalents (April 30, 2020) with no debt and cash runway projected to fund operations into 2H 2021**

**C-SUITE LEADERSHIP TEAM**

- **David Mazzo, PhD**
  - President and Chief Executive Officer
- **Douglas Losordo, MD**
  - Executive Vice President, Global Head of R&D, and Chief Medical Officer
- **Joseph Talamo, CPA, MBA**
  - Senior Vice President and Chief Financial Officer

**MARKET SNAPSHOT**

- **Ticker Symbol**: CLBS
- **Exchange**: NASDAQ
- **52-Week Price Range**: $3.64 - $1.05
- **Shares Outstanding (4/30/2020)**: 12.8 million
- **Cash & Investments (4/30/2020)**: ~$34 million
- **Fiscal Year-End**: December 31

**POTENTIAL VALUE CREATING MILESTONES**

- **2H 2020**: Complete Phase 2 enrollment in CLBS12
- **2H 2020**: J-NDA Rolling Submission Initiation
- **2H 2020**: Initiation of CLBS16 Phase 2 trial
- **3Q 2020**: Initiation of CLBS119 Phase 1/2 trial
- **1H 2021**: Announce Phase 2 CLBS12 top-line data
CD34+ CELL THERAPY PLATFORM

- Naturally occurring vascular repair (endothelial progenitor) cell
- Provokes restorative angiogenesis of the microvasculature
- CD34+ cells re-establish blood flow to under-perfused tissues
- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius’ proprietary platform technology selects and delivers a potent, concentrated population of the patient’s own CD34+ cells for optimal therapeutic benefit.

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Development Stage</th>
<th>Commercialization Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLBS119</td>
<td>COVID-19 Lung Damage</td>
<td>Phase 1/2 (USA; start target 3Q20)</td>
<td>TBD</td>
</tr>
<tr>
<td>CLBS12</td>
<td>CLI</td>
<td>Registration eligible trial (Japan; ongoing)</td>
<td>4Q2021</td>
</tr>
<tr>
<td>CLBS16</td>
<td>CMD</td>
<td>Phase 2 (USA; start target 2H 2020)</td>
<td>TBD</td>
</tr>
<tr>
<td>CLBS14</td>
<td>NORDA</td>
<td>Phase 3 confirmatory (USA; initiation pending funding)</td>
<td>TBD</td>
</tr>
</tbody>
</table>

The information contained herein was obtained from Caladrius Biosciences, Inc. This does not constitute the solicitation of the purchase or sale of securities. Except for the historical information contained in this summary, the matters discussed herein are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Caladrius undertakes no obligation to update or revise any forward-looking statements. For additional information about Caladrius Biosciences and its operations and related risks, please refer to the Company’s SEC filings.

Caladrius © 2020 All rights reserved.

CD34+ CELL THERAPY PIPELINE

- Drug induced mobilization eliminates need for surgical bone marrow aspiration
- No genetic manipulation or ex vivo expansion of cells
- Four days or less from donation to treatment
- Cost-of-goods an order of magnitude less expensive than CAR-T therapies